While off-target effects of B02 (unrelated to RAD51) are possible, they appear unlikely in view of the similar effect on DOX toxicity to MM cells, of siRNA very specifically targeting Rad51. It is especially noteworthy that these synergistic effects of DOX and B02 chemotherapy were substantially greater in MM cells than in peripheral B cells, thus enhancing the therapeutic window for treatment. This evidence concerns the gene RAD51 and Miyoshi myopathy.